Amipaque: a new contrast medium in coronary angiography. Report of a double-blind study in man.
Isopaque Coronar and Amipaque (metrizamide) were evaluated in a comparative double-blind study of 30 patients with heart disease undergoing selective coronary angiography. Amipaque alone was also used for 9 additional patients undergoing left ventriculography, aortic root injection, and selective coronary angiography. Amipaque resulted in significantly less of a decrease in diastolic pressure and heart rate, reduced chest pain and heat sensation, and longer coronary contrast transit time. Electrorocardiographic parameters and image quality were equivalent with the 2 agents. No pathological changes were noted in the 9 patients undergoing complete angiocardiographic study.